Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
24.40
-0.65 (-2.59%)
At close: Feb 26, 2026, 4:00 PM EST
24.10
-0.30 (-1.23%)
After-hours: Feb 26, 2026, 4:00 PM EST
AAPG Employees
Ascentage Pharma Group International had 605 employees as of June 30, 2025. The number of employees increased by 38 or 6.70% since the number was reported on December 31, 2024.
Employees
605
Change
38
Growth
6.70%
Revenue / Employee
$90,123
Profits / Employee
-$267,461
Market Cap
2.24B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 605 | 38 | 6.70% |
| Dec 31, 2024 | 567 | -16 | -2.74% |
| Dec 31, 2023 | 583 | 3 | 0.52% |
| Dec 31, 2022 | 580 | -33 | -5.38% |
| Dec 31, 2021 | 613 | 180 | 41.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Ultragenyx Pharmaceutical | 1,294 |
| Telix Pharmaceuticals | 1,184 |
| Arcus Biosciences | 627 |
| Adaptive Biotechnologies | 619 |
| Galapagos NV | 558 |
| Immunome | 168 |
| Disc Medicine | 142 |
AAPG News
- 13 days ago - Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 20 days ago - Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - GlobeNewsWire
- 5 weeks ago - Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 6 weeks ago - Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment - Benzinga
- 2 months ago - ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP - GlobeNewsWire
- 2 months ago - ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% - GlobeNewsWire